Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Biocon-Limited"

52 News Found

Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications
People | July 23, 2025

Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications

She was Group Chief Marketing Officer at CKA Birla Group in her last role


Biocon concludes a Rs 4,500 crore equity fundraise through QIP
News | June 21, 2025

Biocon concludes a Rs 4,500 crore equity fundraise through QIP

The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures


Biocon gets approval for diabetes drug Liraglutide in India
Diagnostic Center | June 03, 2025

Biocon gets approval for diabetes drug Liraglutide in India

The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus


Peter Bains appointed MD & CEO of Syngene International
People | April 02, 2025

Peter Bains appointed MD & CEO of Syngene International

He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years


Biocon launches GLP -1, Liraglutide, in UK
News | March 01, 2025

Biocon launches GLP -1, Liraglutide, in UK

The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.


Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis
Diagnostic Center | February 07, 2025

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis

Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo


Biocon posts Q3 FY25 PAT at Rs. 25 Cr
News | January 31, 2025

Biocon posts Q3 FY25 PAT at Rs. 25 Cr

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars


Biocon’s S&P Global ESG Score improves to 69 for 2024
Sustainability | January 30, 2025

Biocon’s S&P Global ESG Score improves to 69 for 2024

Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53


Kiran Mazumdar-Shaw honored by ISQ with ‘Jamsetji Tata Award’ for pioneering biosciences movement
News | December 16, 2024

Kiran Mazumdar-Shaw honored by ISQ with ‘Jamsetji Tata Award’ for pioneering biosciences movement

Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International


Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
News | December 12, 2024

Biocon Biologics recognized as Asia IP Elite for 2024 by IAM

Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list